Spyre Therapeutics (NASDAQ:SYRE) Issues Quarterly Earnings Results

Spyre Therapeutics (NASDAQ:SYRE) issued its quarterly earnings results on Thursday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.08, Zacks reports.

Spyre Therapeutics Price Performance

Shares of NASDAQ SYRE traded up $1.33 during trading hours on Friday, reaching $19.70. The stock had a trading volume of 651,522 shares, compared to its average volume of 601,152. The business’s fifty day moving average is $22.45 and its two-hundred day moving average is $26.83. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -2.64 and a beta of 2.85. Spyre Therapeutics has a twelve month low of $18.26 and a twelve month high of $47.97.

Analyst Ratings Changes

Several research analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Robert W. Baird lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 18th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $54.83.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).